After the U.S. Food and Drug Administration’s (FDA’s) Emergency Use Authorization (EUA) of COVID-19 vaccines, blood clots were some of the earliest adverse events observed, and abnormal coagulation continues to be one of the most frequent and serious problems reported.

As of mid-September, the Vaccine Adverse Event Reporting System (VAERS) — notorious for capturing only a minuscule proportion of adverse events — had received notification of more than 43,000 blood clotting disorders, including acute-onset problems in young children.

Clotting disorders make the blood clot “too easily,” generating clots that can travel through the bloodstream and increase the risk of heart attacks and strokes, among other potential complications. …

Continue reading >>>>